Floatz logo

Cediranib

Recurrent Small Lymphocytic Lymphoma

Mayo ClinicSmall moleculePhase 2Active
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Recurrent Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Weill Medical College of Cornell University
Phase 2BBB
Irinotecan
IGM Biosciences, Inc.
Phase 2BBB
Bortezomib
OHSU Knight Cancer Institute
Phase 2BB
Carboplatin
University of Miami
Phase 2BB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BB

View all 50 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →